IGLL3P: A Key Regulator of Immune and Neurodegenerative Diseases

Target Name: IGLL3P

NCBI ID: G91353

IGLL3P

Other Name(s): IGLL3 | 16.1 | immunoglobulin lambda like polypeptide 3, pseudogene | Immunoglobulin lambda like polypeptide 3, pseudogene

IGLL3P: A Key Regulator of Immune and Neurodegenerative Diseases

IGLL3P, or interleukin-3-like peptide-3, is a protein that is expressed in various tissues throughout the body. It is a key regulator of immune responses and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

One of the unique features of IGLL3P is its ability to self-cleave, meaning that it can break down into its constituent amino acids on its own. This process, known as tryptophan cleavage, is a key mechanism by which IGLL3P regulates its own expression and function.

IGLL3P has been shown to play a key role in the regulation of immune responses both in the context of cancer and autoimmune disorders. In cancer, IGLL3P has been shown to promote the development and progression of various types of cancer, including breast, lung, and colon cancer. This is achieved through a variety of mechanisms, including the regulation of cell proliferation, the production of pro-inflammatory cytokines, and the inhibition of apoptosis.

In addition to its role in cancer, IGLL3P has also been implicated in a number of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. In these disorders, IGLL3P has been shown to contribute to the development and maintenance of autoimmune responses, leading to inflammation, tissue damage, and other symptoms.

IGLL3P has also been shown to play a role in the regulation of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In these disorders, IGLL3P has been shown to contribute to the development and progression of neurodegeneration, leading to the loss of brain cells and the development of neurofibrillary tangles.

In addition to its role in disease, IGLL3P has also been shown to have potential as a drug target. Several studies have shown that IGLL3P can be effectively targeted with small molecules, including inhibitors of its tryptophan cleavage and other mechanisms. These small molecules have been shown to have a variety of therapeutic effects, including the inhibition of cancer cell growth, the regulation of autoimmune responses, and the improvement of neurodegenerative symptoms.

Overall, IGLL3P is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these diseases and to develop effective treatments based on its properties.

Protein Name: Immunoglobulin Lambda Like Polypeptide 3, Pseudogene

The "IGLL3P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLL3P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets